Search clinical trials for: BIA 2-093

Total 72180 results

Bial - Portela C S.A.

Completed

Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

Epilepsy

Romania
Bial - Portela C S.A.

Completed

A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093

Epilepsy
Bial - Portela C S.A.

Completed

The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites

Epilepsy

Germany
Bial - Portela C S.A.

Terminated

The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093

Epilepsy

United Kingdom
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures

Epilepsy
Bial - Portela C S.A.

Completed

A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093

Epilepsy

United Kingdom
Bial - Portela C S.A.

Completed

Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia

Fibromyalgia
Bial - Portela C S.A.

Completed

Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder

Bipolar I Disorder
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)

Epilepsy

Portugal
Bial - Portela C S.A.

Terminated

Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain

Painful Diabetic Neuropathy

Portugal
Bial - Portela C S.A.

Completed

A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers

Epilepsy

Portugal
Five Eleven Pharma, Inc.
Indiana University

Active, not recruiting

Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer

Prostate Cancer | Prostate Cancer Recurrent

United States
Mundipharma Research Limited

Completed

Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With Asthma

Asthma

Romania, Hungary, Czechia, France, Germany, Poland
Merrimack Pharmaceuticals

Completed

Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis

Psoriasis

United States
Bial - Portela C S.A.

Terminated

Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia

Post Herpetic Neuralgia

Germany
Peking Union Medical College Hospital

Not yet recruiting

68Ga-P16-093 PET/CT Imaging in the Salivary Gland

Primary Sjögren Syndrome
Peking Union Medical College Hospital

Recruiting

68Ga-P16-093 PET/CT Imaging in Glioma Patients

Glioma

China
Five Eleven Pharma, Inc.

Active, not recruiting

Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer

Prostate Cancer | Renal Cancer

United States
Bial - Portela C S.A.

Completed

Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function

Epilepsy
Merrimack Pharmaceuticals

Completed

Phase 2 Study of MM-093 to Treat Patients With Uveitis

Uveitis

United States
Bial - Portela C S.A.

Completed

A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers

Epilepsy

United States
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children

Partial Epilepsy in Children and Adolescents

United Kingdom, Spain, Serbia, Italy, Austria, Bosnia and Herzegovina, Croatia, Czechia, France, Germany, Hungary, Malaysia, Moldova, Republic of, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Taiwan, Ukr...
Bial - Portela C S.A.

Completed

Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Epilepsy

South Africa
Bial - Portela C S.A.

Completed

An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Epilepsy

South Africa
Bial - Portela C S.A.

Completed

Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation

Epilepsy
Peking Union Medical College Hospital

Recruiting

68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients

Prostate Cancer

China
Bial - Portela C S.A.

Completed

The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

Epilepsy
Bial - Portela C S.A.
Sunovion

Completed

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

Partial Epilepsy

United States, Argentina, Germany, France, Belgium, Canada, Italy, Poland, Greece, Brazil, Cyprus
Bial - Portela C S.A.

Completed

Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate

Epilepsy
Sunovion

Completed

Eslicarbazepine Acetate Monotherapy Long Term Study

Epilepsy

United States, Canada, Bulgaria, Ukraine, Czechia, Serbia
Bial - Portela C S.A.

Completed

Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093

Epilepsy

Portugal
Peking Union Medical College Hospital

Recruiting

68Ga PET/CT Imaging in Breast Cancer Patients

Breast Cancer

China
Bial - Portela C S.A.

Completed

Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures

Partial Epilepsy

Netherlands, Poland, Italy, Russian Federation, Ukraine
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

Bipolar I Disorder
Bial - Portela C S.A.

Completed

Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine

Epilepsy

Germany
Peking Union Medical College Hospital

Recruiting

68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients

Prostate Cancer

China
Bial - Portela C S.A.

Completed

Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate

Epilepsy
University of Michigan
The Gerber Foundation

Recruiting

Predicting Peanut Anaphylaxis and Reducing Epinephrine (PrePARE)

Anaphylaxis Food

United States
Memorial Sloan Kettering Cancer Center
New York Presbyterian Hospital; Rockefeller University

Completed

Improving Therapeutic Outcomes in the Tongue Carcinoma Patient: Assessment of Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging

Tongue Carcinoma

United States
Bial - Portela C S.A.

Completed

Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Epilepsy

Portugal
Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Recruiting

Talocalcaneal Angle in Calcaneal Spur Formation

Plantar Fascitis | Foot Callus

Turkey
Bial - Portela C S.A.

Terminated

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

BIPOLAR I DISORDER
Mersin University

Recruiting

Effects of Information-Motivation-Behavioral Skills Model on Disease Management of Adolescents With Epilepsy

Nursing Caries

Turkey
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); The City College of New York; DOWNSTATE MED/KINGS... and other collaborators

Active, not recruiting

Risk Factors for Endometrial Cancer in Black Women

Endometrial Cancer

United States
Peking Union Medical College Hospital

Completed

68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients

Clear Cell Renal Cell Carcinoma

China

3

Subscribe